A method for extracting a ceramide-containing material or ceramide from whole apples and/or apple juice extraction residue. Furthermore, to ensure utility as a food, especially a functional food, or a raw material for a cosmetic or medicine, that includes the ceramide-containing material. [Solution] In the present invention, an adsorbent is added to an ethanol treatment solution of whole apples and/or apple juice extraction residue, the mixture is stirred and subjected to solid-liquid separation, and solid material precipitated from the solution is separated, after which water is added to the resultant concentrate and the temperature thereof is maintained, whereby the resultant settled component is recovered and dried to obtain a ceramide-containing material or ceramide. Using the ceramide obtained from whole apples and/or apple juice extraction residue, there are formed a composition for promoting production of hyaluronic acid and/or type II collagen, and a composition for promoting improvement of memory impairment and/or enhancement of the level of phosphorylation of extracellular signal-related kinases (ERK1/2).

A method for extracting a ceramide-containing material or ceramide from whole apples and/or apple juice extraction residue. Furthermore, to ensure utility as a food, especially a functional food, or a raw material for a cosmetic or medicine, that includes the ceramide-containing material. [Solution] In the present invention, an adsorbent is added to an ethanol treatment solution of whole apples and/or apple juice extraction residue, the mixture is stirred and subjected to solid-liquid separation, and solid material precipitated from the solution is separated, after which water is added to the resultant concentrate and the temperature thereof is maintained, whereby the resultant settled component is recovered and dried to obtain a ceramide-containing material or ceramide. Using the ceramide obtained from whole apples and/or apple juice extraction residue, there are formed a composition for promoting production of hyaluronic acid and/or type II collagen, and a composition for promoting improvement of memory impairment and/or enhancement of the level of phosphorylation of extracellular signal-related kinases (ERK1/2).

Methods and compositions for treating cancer are provided. Compositions comprising ceramide nanoliposomes are administered to a subject in need of such treatment. The composition administration also enhances immunotherapy. Further administering compositions in combination with tumor antigen specific T-cells, and/or compositions in combination with tumor antigen expressing cells, and/or said compositions in combination with antagonists of PD-1 provides for enhanced results. Administration of the compositions provides for effective treatment of tumors including regression and eradication of established tumors.

Methods and compositions for treating cancer are provided. Compositions comprising ceramide nanoliposomes are administered to a subject in need of such treatment. The composition administration also enhances immunotherapy. Further administering compositions in combination with tumor antigen specific T-cells, and/or compositions in combination with tumor antigen expressing cells, and/or said compositions in combination with antagonists of PD-1 provides for enhanced results. Administration of the compositions provides for effective treatment of tumors including regression and eradication of established tumors.

The present disclosure relates to modified or polymer conjugated MetAP2 inhibitors. The present disclosure also relates to methods of treating, or ameliorating at least one symptom of, metabolic dysfunction associated with a treatment in a subject having cancer. The present disclosure also relates to methods of treating, or ameliorating at least one symptom of, cancer comprising administering a combination of a polymer conjugated MetAP2 inhibitors and at least one second agent.

The present disclosure relates to modified or polymer conjugated MetAP2 inhibitors. The present disclosure also relates to methods of treating, or ameliorating at least one symptom of, metabolic dysfunction associated with a treatment in a subject having cancer. The present disclosure also relates to methods of treating, or ameliorating at least one symptom of, cancer comprising administering a combination of a polymer conjugated MetAP2 inhibitors and at least one second agent.

[Problem] Provided is a non-peptide compound which can be used as a GAPDH aggregation inhibitor. [Solution] Provided is a GAPDH aggregation inhibitor including as an active ingredient a compound represented by the chemical formula 1 wherein R.sub.1, R.sub.2, and R.sub.3 are each independently a hydrogen atom, a halogen atom, or an aliphatic hydrocarbon group having a carbon number of from 1 to 10, a polysulfurized derivative thereof, or a pharmaceutically acceptable salt thereof. The present compound has a GAPDH aggregation inhibitory activity to suppress intracerebral aggregation of various proteins involved in cerebral neurodegenerative diseases, thereby contributing to improvement in various brain neurological diseases associated with aggregation of these proteins such as Alzheimer's disease, Parkinson's disease, and cerebral infarction, and prevention of advanced seriousness of these diseases. ##STR00001##

[Problem] Provided is a non-peptide compound which can be used as a GAPDH aggregation inhibitor. [Solution] Provided is a GAPDH aggregation inhibitor including as an active ingredient a compound represented by the chemical formula 1 wherein R.sub.1, R.sub.2, and R.sub.3 are each independently a hydrogen atom, a halogen atom, or an aliphatic hydrocarbon group having a carbon number of from 1 to 10, a polysulfurized derivative thereof, or a pharmaceutically acceptable salt thereof. The present compound has a GAPDH aggregation inhibitory activity to suppress intracerebral aggregation of various proteins involved in cerebral neurodegenerative diseases, thereby contributing to improvement in various brain neurological diseases associated with aggregation of these proteins such as Alzheimer's disease, Parkinson's disease, and cerebral infarction, and prevention of advanced seriousness of these diseases. ##STR00001##

The invention features the use of cysteamine precursor compounds for the treatment and prophylaxis of severe symptoms of betacoronavirus infections, such as infections by SARS-CoV-2, SARS-CoV-1, MERS-CoV, and related viruses.

In one aspect, the invention relates to compounds having the formula: ##STR00001##
where R.sup.1-R.sup.6, a, b, and Z are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.